Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kairos Pharma (KAPA) Retained Earnings (2024 - 2025)

Kairos Pharma's Retained Earnings history spans 2 years, with the latest figure at -$14.3 million for Q4 2025.

  • For Q4 2025, Retained Earnings fell 61.79% year-over-year to -$14.3 million; the TTM value through Dec 2025 reached -$14.3 million, down 61.79%, while the annual FY2025 figure was -$14.3 million, 61.79% down from the prior year.
  • Retained Earnings reached -$14.3 million in Q4 2025 per KAPA's latest filing, down from -$11.5 million in the prior quarter.
  • In the past five years, Retained Earnings ranged from a high of -$7.8 million in Q3 2024 to a low of -$14.3 million in Q4 2025.